Endocyte, Inc. (NASDAQ:ECYT) has not provided investors with a whole lot of confidence over the past year, as the stock has moved -32.91% during that time frame.
Looking closer at near term results should notice that shares are 1.62% over the past five trading days. Looking further out, the stock is -21.70% year to date. With increased market volatility, stakeholders will likely be deciding whether or not now is a good time to cut losses or double down for the long haul.
Wall Street analysts are still seeing some upside to the stock despite the disappointing year. Sell-side firms, on a consensus basis have a $7.50 price target on the name and a 2.00 recommendation, according to First Call. The recommendation is based on a 1 to 5 scale where 1 or 2 indicates a Buy recommendation, 3 a Hold and 4-5 a Sell.<!–
Endocyte, Inc. (NASDAQ:ECYT) has posted trailing 12 months earnings of $-1.05 per share. The company has seen a change of -852.70% earnings per share this year. Analysts are predicting -8.00% for the company next year. The firm is yielding -25.40% return on assets and -26.30% return on equity. –>
In taking a look at technical levels, shares are trading 1.13% away from the 50 day simple moving average and -6.91% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -44.23% away from it’s 52- week high and 18.49% away from its 52 week low. After the recent increase, investors may also look to see if the stock has entered overbought territory and could possibly ripe for a pullback. Traditionally a stock is considered to be overbought when the Relative Strength Index moves above 70. As of writing, Endocyte, Inc.’s RSI stands at 50.39 . In looking at volatility levels, the shares saw weekly volatility of 5.96% and 4.97% over the past month.
Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts.
Endocyte, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.